Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,470 | 5日内发货 | ||
5 mg | ¥ 2,490 | 5日内发货 | ||
25 mg | ¥ 9,160 | 6-8周 | ||
50 mg | ¥ 11,900 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,630 | 5日内发货 |
产品描述 | HBV-IN-4, a derivative of phthalazinone, functions as a potent, orally active inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. It effectively induces the formation of genome-free capsids, demonstrating significant anti-HBV potency[1]. |
靶点活性 | HBV DNA replication:14 nM (IC50) |
体外活性 | HBV-IN-4 (compound 19f; 0-1 μM; 8 days) treatment inhibits the various forms (relaxed circular [rc] and single-stranded [ss] HBV DNA) in a dose-dependent manner in HepG2.2.15 cells. HBV-IN-4 treatment could also reduce capsidassociated DNAs dose-dependently. HBV-IN-4 could induce the formation of genome-free capsids, including a phenotype of faster-migrating ones[1]. |
体内活性 | HBV-IN-4 (Compound 19f; 50-150 mg/kg; oral administration; twice a day; for 4 weeks; Balb/c male mice) treatment achieves 2.67 log viral load reduction in AAV-HBV/mouse model[1].HBV-IN-4 (compound 19f) exhibits favorable drug characteristics with low plasma clearance (CL=4.1 mL/min/kg), excellent drug exposure (AUC0-t=49 744 h?ng/L), T1/2 (2.15 hours) and oral bioavailability (F=60.4%) using 20 mg/kg oral administration in mice. HBV-IN-4 also shows good distribution in liver exposure[1]. |
分子量 | 479.89 |
分子式 | C24H19ClFN5O3 |
CAS No. | 2305897-84-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (208.38 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0838 mL | 10.4191 mL | 20.8381 mL | 52.0953 mL |
5 mM | 0.4168 mL | 2.0838 mL | 4.1676 mL | 10.4191 mL | |
10 mM | 0.2084 mL | 1.0419 mL | 2.0838 mL | 5.2095 mL | |
20 mM | 0.1042 mL | 0.521 mL | 1.0419 mL | 2.6048 mL | |
50 mM | 0.0417 mL | 0.2084 mL | 0.4168 mL | 1.0419 mL | |
100 mM | 0.0208 mL | 0.1042 mL | 0.2084 mL | 0.521 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
HBV-IN-4 2305897-84-9 HBV IN 4 HBVIN4 Inhibitor inhibitor inhibit